Stockscreener 앱 받기
1.55
3.33%
0.05
시간 외 거래:
1.55
전일 마감가:
$1.50
열려 있는:
$1.51
하루 거래량:
1.16M
Relative Volume:
0.99
시가총액:
$357.01M
수익:
$14.56M
순이익/손실:
$-63.37M
주가수익비율:
-5.5695
EPS:
-0.2783
순현금흐름:
$-19.44M
1주 성능:
-1.90%
1개월 성능:
-12.92%
6개월 성능:
+1.31%
1년 성능:
+213.51%
1일 변동 폭
$1.465
$1.56
1주일 범위
$1.465
$1.71
52주 변동 폭
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.55 | 345.49M | 14.56M | -63.37M | -19.44M | -0.2783 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Insider Buying: Brian Culley Acquires 15,000 Shares of Lineage C - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 15,000 Shares - MarketBeat
Lineage Cell Therapeutics (LCTX) CEO adds 15,000 shares in open-market purchase - Stock Titan
Lineage Cell Therapeutics, Inc. Files Form 8-K for At-The-Market Offering – Key Company and Security Information (LCTX, NYSEAMER) 232425 - Minichart
Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs - MSN
Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering - Investing.com
Lineage Therap Expands ATM Equity Offering Capacity - TipRanks
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM equity offering - TradingView
Lineage Cell Therapeutics (LCTX) files $100M shelf to issue shares, debt, warrants - Stock Titan
Lineage Cell (NYSE: LCTX) files supplement for $60M ATM shares - Stock Titan
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 earnings call transcript - MSN
US Market Wrap: Is Klotho Neurosciences Inc gaining market shareGap Down & Daily Technical Forecast Reports - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Lineage Cell Therapeutics (LCTX) Mar 2026 - Meyka
Lineage Cell Therapeutics Extends Runway Amid R&D Surge - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why Lineage Cell Therapeutics Inc. stock could outperform in 2026Portfolio Performance Summary & Free Verified High Yield Trade Plans - Naître et grandir
Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges - TipRanks
Can Lineage Cell Therapeutics Inc. stock resist market sell offsQuarterly Growth Report & Long Hold Capital Preservation Plans - Naître et grandir
Risk Off: Is Lineage Cell Therapeutics Inc stock overvalued or fairly pricedJuly 2025 Momentum & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Lineage Cell (LCTX) grants CFO 1.05M employee stock options - Stock Titan
Lineage Cell Therapeutics (LCTX) grants 900,000 stock options to General Counsel - Stock Titan
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $3.00 - MarketBeat
LCTX Stock Rating Maintained as Buy; Price Target Raised by D. B - GuruFocus
H.C. Wainwright reiterates Buy on Lineage Cell stock, $9 target - Investing.com South Africa
Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Lineage Cell Therapeutics (LCTX) Extends Cash Runway with Positi - GuruFocus
Earnings Call Summary | Lineage Cell Therapeutics(LCTX.US) Q4 2025 Earnings Conference - 富途牛牛
Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides B - PharmiWeb.com
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4 - Yahoo Finance
Lineage Cell Therapeutics (LCTX) Sees Revenue Surge in Q4 - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Lineage Cell Therapeutics posts fourth quarter and full year 2025 financial results ahead of update call - Traders Union
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
LCTX,BTX Volatility & Greeks - Finviz
Lineage Cell Therapeutics (LCTX) Q4 Earnings Preview: Key Expectations - GuruFocus
A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast - Benzinga
LCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Lineage Cell Therapeutics (LCTX) to Release Earnings on Monday - MarketBeat
Lineage Cell Therapeutics IncWithdrew CIRM Grant Application Filed In June 2025SEC Filing - TradingView
Is now the right time to enter Lineage Cell Therapeutics Inc2025 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
LCTX PE Ratio & Valuation, Is LCTX Overvalued - Intellectia AI
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide - PharmiWeb.com
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Yahoo Finance
Institution Moves: How does Lineage Cell Therapeutics Inc compare to its peersJuly 2025 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):